Abstract With the emergence of the cancer stem cell hypothesis in leukemia there has been a need to develop the crucial tools and assays to prospectively isolate these cells from other cancers. This review focuses on the latest strategies to prospectively isolate cancer stem cells and also explores some of the caveats of the methodology that has taken hold. Emerging themes in the cancer stem cell field will be explored, including relevance of cell of origin, intraclonal heterogeneity, and how exploiting the unique functional attributes of stemness in the cancer stem cell population can refine approaches to isolate these cells from various malignancies.
Introduction
Cancers are comprised of genetically, phenotypically and functionally heterogeneous cell populations, yet it is also known that they are clonal in their nature [1] . The coexistence of the seemingly mutually exclusive features of heterogeneity and clonality in individual malignancies can be reconciled by the cancer stem cell (CSC) hypothesis [2] . This hypothesis suggests that neoplasms are organized as cellular hierarchies and that initiation and maintenance of growth in a given cancer is carried out by a unique and usually infrequent subset of CSCs. A central tenet of this model is that it must be possible to prospectively isolate a subset of the cancer population that has the unique capacity (not shared by the bulk of the cancer) to initiate and propagate the disease. In this respect, the CSC model hypothesizes a structure in cancer that is analogous to the hierarchal organization of normal tissues [3] , such as the hematopoietic system, where blood cell production is maintained by phenotypically and functionally unique hematopoietic stem cells (HSC) that divide into increasingly lineage-restricted intermediates which ultimately differentiate into mature cells. In the CSC model, instead of contributing normal functioning differentiated cells for tissue homeostasis, CSCs drive deregulated clonal expansion of non-tumor initiating neoplastic cells that are phenotypically and functionally diverse. With the introduction of the CSC hypothesis and the seminal discovery of CSCs in acute myeloid leukemia (AML) [4, 5] , there has been great interest over the last decade to develop the crucial tools and assays to prospectively isolate these cells from other cancers. Historically, prospective isolation was essential for the first validation that a given cancer conforms to the CSC model. At the present time however, interest has turned to refinement of these isolation parameters in order to more precisely pinpoint the CSC population so that we might better define its molecular state and thus develop more targeted and effective therapies. Advances that would allow rare CSCs to be conclusively identified are also sought in order to facilitate the characterization of their behavior in situ. The realization that CSCs are also dynamic entities subject to evolutionary changes previously thought to be manifest by more downstream cell types is a very recent finding. This discovery has meant that prospective isolation of multiple CSC subclones within single cancers can also provide important information on crucial genetic and epigenetic drivers of cancer progression.
In this review we will discuss the current state of prospective CSC isolation and the various strategies that are used to facilitate this. We will also highlight recent concepts and emerging controversies in the field that will necessitate consideration as more and more efforts are put into achieving true CSC purification from an increasing array of human malignancies. Lastly we will explore some of the novel approaches that are beginning to address the issue of prospective isolation by exploiting the unique functional attributes of stemness in CSC populations.
Identification of Cancer Stem Cells

A Historical Perspective
Studies involving human AML demonstrated the first direct evidence for the existence of CSCs [4, 5] . This work showed that the cell population marked by the surface marker phenotype CD34
? CD38 -, which is where normal HSCs reside, was the only population capable of giving rise to AML in non-obese diabetic severe immune deficient (NOD-SCID) mice. The AML engrafted in these mice resembled the original leukemia and could be serially transplanted. These initial studies provided the first direct evidence for the hierarchical organization of cancer with leukemic stem cells (LSC) at the apex of a dysregulated developmental hierarchy, and established the NOD-SCID xenotransplantation assay as the model of choice to test the CSC paradigm in other cancers.
The first identification of CSCs from a solid tumor was the discovery of a specific population of human breast cancer cells that were able to give rise to tumors in NOD-SCID mice [6] . Specifically, as few as 100 CD44 ?
CD24
-/lo breast cancer cells were able to initiate tumors in the fat pads of immunocompromised mice, yet tens of thousands of the remaining cells were unable to form tumors. Notably, these tumors could be serially transplanted giving rise to further populations of CD44 ?
-/lo tumor initiating cells (TIC) as well as phenotypically diverse non-TICs, providing distinct evidence for a specific self-renewing population with the capability of also recapitulating the heterogeneity of the original tumor. With this demonstration that CSCs exist in a neoplasm other than leukemia, the entry of those into the search for CSCs in other cancers was rapid. The CD133 ? glioblastoma and medulloblastoma cells were next identified as CSCs with the use of neurosphere assays and xenograft transplantation [7, 8] . At the present time, exhaustive testing for CSCs through trial and error exploration of the ability of surface markers as well as specific cellular functions to enrich for CSCs has culminated in evidence for their existence in other cancers including colon [9] , pancreatic [10, 11] , head and neck [12] , and liver [13] (Table 1 ).
The State of the Art
There currently exist three standard methods by which CSCs are routinely enriched for. These consist of isolating cells (i) based on the presence and/or absence of a specific combination of cell surface markers, also known as immunophenotyping, (ii) based on their capacity to efflux Hoechst 33342 and (iii) based on the activity of the enzyme aldehyde dehydrogenase (ALDH). Of these approaches, immunophenotyping has been relied on most heavily, but typically involves a fairly iterative process, the first step of which is the attempt to purify based on marker expression identified in other cancer types or based on the known phenotype of the analogous tissue stem cell. In some cases, the use of negative selection for markers found upregulated in the bulk tumor actually improves the separation [6] . The further refinement of immunophenotypes is also often achieved by incorporating antibodies against additional surface antigens detected as differentially expressed in modestly CSC-enriched subsets [14] . It is important to note that in the above cases immunophenotypes that can substantially purify CSC populations are arrived at by significant trial and error attempts, each time requiring purification then lengthy transplantation assays before CSCs are or are not read out.
The enhanced ability of tissue stem cells to efflux the dye Hoechst 33342, and to therefore be isolatable in what was termed the ''side population (SP)'' or Hoechst low subset was first shown in the murine hematopoietic system by Goodell and colleagues [15] . This capacity was later traced to the elevated expression of multidrug ABC membrane transporters [16] . The SP phenotype has since been applied to multiple cancers, and, in some cases, can enrich for the fraction of cells that has tumor initiating capacity [17] . Though this particular method of prospectively isolating CSCs is attractive in that it appears to be capitalizing on a presumably important mechanism of drug resistance that the CSC subset has uniquely exploited, caveats remain. Critics of the approach, for instance, suggest that toxicity may be an issue for the cells that cannot efflux efficiently, thus precluding their engraftment potential.
Finally, the use of ALDH activity to separate out CSCs is a fairly recent development. ALDHs irreversibly catalyze the conversion of cellular aldehydes to their corresponding acid form. Detection of cells expressing ALDHs can be achieved using the ALDEFLUOR dye which is oxidized by these enzymes leading to the accumulation of a fluorescent product [18] . As well as specifying normal stem cell populations [18, 19] , ALDH activity has been found to be associated with CSC subsets in multiple leukemias and solid tumor types [20, 21] . Importantly, this method of separation, similarly to Hoechst efflux, relies on a functional capacity inherent for the more primitive cells of a cancer, but, in contrast, is not thought to impart toxicity to the labeled cells.
The precise role of ALDHs in stem cell and CSC populations remains to be determined, though it is hypothesized that since ALDH oxidizes intracellular vitamin A to produce retinoic acid [22] this could promote signaling through various retinoic acid receptors (RAR) [23] . The role of RARs in cancer is complex, since loss of function, overexpression or mutation results in deregulation of normal tissue self renewal and differentiation programs [23] . Additionally, Aldh2 activity has been shown to protect HSCs from DNA damage due to accumulated acetaldehydes [24, 25] . Thus, the role of ALDH in RAR signaling and as a detoxifying enzyme of intracellular metabolites implicates its pleiotropic cellular effects. This will be important to consider before fully appreciating how ALDH can effectively mark various CSCs.
Experimental Considerations
Limitations to Immunophenotyping
The use of immunophenotyping to facilitate the extraction of CSCs from heterogeneous cancer populations was essential for the first validation of the CSC model and has undoubtedly been a critical tool in the search for and characterization of new CSCs. Nonetheless, reliance on surface marker expression as the lone means to purify these cells is not without its limitations. Separation of CSC function from a well-defined immunophenotype, for instance, has been shown in mouse models of leukemia [26 •• ]. In this study, introduction of the HoxA9-Meis1 oncogenic fusion protein drove LSC formation leading to AML initiation. Importantly, using phenotypes normally associated with distinct populations of HSC, primitive progenitors and committed non-self-renewing progenitors, the authors were able to isolate three separate populations of LSC all of which gave rise to each other when transplanted in secondary recipients.
The most fascinating aspect of this work is that despite their phenotypic uniqueness, these LSCs shared underlying signaling networks that overlap with leukemic and normal HSC gene signatures. Another technical aspect that could bias identification and assessment of CSC populations is the antibodies used. It has been found that in some cases the reason for the masking of LSC potential in the CD34
? CD38 ? fraction of some human AMLs is recognition of anti-CD38 coated cells and their clearance by the residual innate immune system in NOD-SCID mice [28] . Treating NOD-SCID mice with anti-CD122 antibody to block NK cell activity, using more immune-deficient mouse strains, and injecting cells directly into the bone marrow eliminated the nonleukemia initiating phenotype of some CD38
? cells. Discrepancies with immunophenotyping CSC populations have also been shown with the surface marker CD133 [32] . The AC133 antibody clone recognizes a glycosylated epitope of CD133 [33] and has been the primary antibody used to identify CSCs in a variety of cancers (Table 1 ). An important question that is rarely addressed is whether CD133
-populations are expressing unglycosylated versions of CD133 or not expressing the protein at all. This was tested in a recent study that examined if AC133 correlated with mRNA and protein expression in a colon CSC model [34] . Intriguingly, they found that expression of CD133 mRNA and protein was unchanged during in vitro differentiation of these cells, but detection by AC133 was only in the undifferentiated CSCs. This work showed that in this context only the glycosylated epitope of CD133 is lost upon CSC differentiation, and at the same time provided important renewed support for CD133, in its glycosylated form, as a CSC marker.
Utility of Xenotransplant Assays in CSC Evaluation
Mouse strain immunogenicity and the transplant method can impart biases for the ability of transplanted human CSCs to engraft and proliferate. A comparison of cancer growth in NOD-SCID and NSG mice was recently done in AML [35] and pancreatic, non-small cell lung, and head and neck carcinomas [36] . In both studies, limiting dilution assays showed an increase in the TIC frequency with the more immune deficient NSG strain; however, both studies demonstrated that regardless of what mouse strain was used, the overall TIC frequency remained low. These studies highlight that for these cancers, growth is controlled by a distinct and rare population of cells and that this does not dramatically change with the mouse model used. On the other hand, there is a profound effect on the frequency of TICs in human melanoma when different mouse strains are used. When ABCB5
? immunophenotyped populations of human melanoma cells were injected into NOD-SCID mice, the frequency of TICs was estimated to be approximately 1 in 10 6 cells, suggesting this cancer followed the CSC model
. This was again countered by a study from Quintana et al. [40] demonstrating that neither CD271 nor 21 other differentially expressed surface markers enriched for melanoma TICs. Conflicting results aside, these studies illustrate how important the technical details of the xenotransplant assay are.
While residual immunogenicity of certain mouse strains can, in some cases, obscure productive tumor initiation, other reasons for the inability of these populations to read out in these models could be the absence of essential microenvironmental components and/or growth factors. Recent efforts to create growth factor transgenic immunodeficient mice expressing human GM-CSF, IL-3 and SCF have demonstrated that provision of these human factors can greatly increase the repopulation capacity of transplanted AML cells as well as yield LSC readout in populations that would not elicit leukemic engraftment in NSG alone [41, 42] . As is clear from these studies and those described above, there are many issues that need to be carefully considered in the choice of transplant assay. The method of cell preparation, mouse model selected and even the injection method can be critical to whether a specific cancer will be observed to follow the CSC model.
Emerging Concepts
Identifying the Cell of Origin in Cancer
In human cancer it is difficult to determine the identity of the original cell that incurred successive mutations and selection to become tumorigenic. Given the similarities that could be expected to exist between its earliest ancestor and the CSC itself, the importance of determining a CSC's cell of origin as a means of improving its purification should not be underestimated. It appears that in AML, LSCs tend to be isolated from, and share, similar transcriptional programs to their normal HSC and progenitor counterparts [29, 31] . Though this data is consistent with a primitive cell-of-origin model in human AML, definitive proof that transformation consistently occurs in a hematopoietic stem cell, a primitive multipotent progenitor or both has not been shown. In the mouse system, transformation of both hematopoietic stem and progenitor populations into LSCs through the virally-mediated overexpression of known oncogenes has been achieved [43, 44] ; however, it is difficult to determine how closely these experimental conditions mirror the oncogenic dose and sequence of events that actually occurs in situ.
Relying on elegant lineage tracing approaches, compelling evidence has been put forth that mouse models of glioblastomas [ -and Lgr5 ? cells, both populations of which were capable of in vivo tumor initiation. This demonstrates that given the appropriate pathway activation, differentiated, non-self renewing cells can give rise to CSCs and importantly, cellular phenotype can change as a result of these alterations. Thus, unless the cellular changes acquired as a result of the initiating mutations are understood, discerning the cell of origin for a given tumor type may provide little additional insight into how the derived CSC might be prospectively identified.
As well as solving an interesting theoretical question, there may be significant therapeutic implication to identifying the Tumor Heterogeneity and Evolution-The Dynamic Nature of CSCs
The prospective isolation of CSCs using the methods outlined in this review (e.g., cell surface marker phenotyping) is particularly subject to the inherent heterogeneity that exists in cancers. Within a specific cancer there is a diversity of different mutations and/or chromosomal aberrations leading to multiple molecular and cytogenetic subtypes of the disease. However, genetic heterogeneity also exists within a patient's tumor or leukemia [59] in the form of genetically distinct clones. Intraclonal genetic heterogeneity and evolution is not a new idea [1] ; however, the genomic sequencing technologies to demonstrate it robustly have only recently been developed [60] [61] [62] [63] [64] . These studies highlight that within a patient's breast, leukemia, or pancreatic cancer there tends to be a dominant clone comprising the majority of the primary tumor in addition to numerous genetically similar subclones. When examining pancreatic metastasis [61] , acute leukemia from myeloid dysplasia [63] or leukemia relapse after chemotherapy [64] the aggressive secondary tumors originated from clones of the primary neoplasm, but had incurred additional mutations which allowed selective growth advantages. Intraclonal heterogeneity was also demonstrated in clear-cell renal carcinoma [65] . When Gerlinger and colleagues biopsied different regions of a patient's primary tumor or metastasis and performed genomic analyses they found about two-thirds of mutations were not shared between regions of the same tumor and that there could be different mutations of the same driver genes in the different regions sampled. Although the CSC hypothesis was not specifically tested in these studies it is possible that CSCs are the culprits for the maintenance of the numerous intratumor clones and are the cells that undergo selection and mutation to establish metastatic and secondary tumors [2] .
The merging of intraclonal genetic heterogeneity with the CSC hypothesis was recently espoused by Mel Greaves [2] and is supported by novel experimental work from his lab and that of John Dick's [66 • , 67 • ]. In these studies clonal tracking in human acute lymphoblastic leukemia was performed using multiplex fluorescence in situ hybridization [66 • ] or genome-wide SNP arrays [67 • ]. Though different methods were used, both studies showed a branching clonal evolution model where multiple genetic subclones compete for repopulation in tumor xenografts. These findings are supported from earlier work that tested heterogeneity in CSCs through clonal analysis of lentiviral marked patient AML [68] . Hope et al., were the first to demonstrate that AML clones in xenografted mice display varying repopulating activity upon secondary and tertiary transplantation. The differences in repopulation kinetics could have been due to genetic heterogeneity within lentiviral marked clones; however, the requisite genomic techniques to test this were not yet available. Given the likelihood that most lentiviral marked clones were of a single dominant genetic clone [64] , it is also possible that non-genetic factors such as epigenetic mechanisms or signals from the microenvironment could have affected repopulation. This idea was recently explored more thoroughly in a xenotransplant model of colorectal cancer [69] . Kreso et al., demonstrated that serial transplantation of colorectal tumor cells did not dramatically change the genomic profile from the primary tumor indicating that tumor clones were stable over in vivo passaging. When they combined this analysis with clonal lentiviral tracking they found that similar to what was seen by Hope et al., there were different lentiviral marked clones that displayed varying tumor initiating capacity upon serial transplantation. The conclusion drawn from these findings was that non-genetic factors could dictate whether a specific clone drives tumorigenesis and in turn contributes to intraclonal heterogeneity. The mounting evidence that CSCs are subject to evolutionary changes and that this is coupled with stochasticity in cell behaviour influenced by intrinsic or extrinsic cues demonstrates that there can be multiple functional CSC subclones within single cancers.
Novel Approaches for Prospective CSC Isolation
Since their initial discovery, identification and isolation of CSCs has primarily relied on searching for CSCs in subsets of cells that share similar phenotypes with their normal tissue stem cell counterparts. As has been discussed above, this approach fails in situations where these surface markers are not represented on the cell of origin and/or are dysregulated as a result of transforming mutations that occur in the process of CSC generation. Another difficulty with immunophenotyping is that markers that have been relied on for decades in the purification of normal stem cells are in many cases uncharacterized in terms of their functional contribution to stemness. What are needed are faithful reporters of stem cell behaviour that are maintained regardless of the stage of the disease or passage in culture (Fig. 1) . Precedents do exist for the successful use of such reporters in other stem cell types as evidenced by the robust selection for pluripotent cells using the EOS reporter, a lentivector that utilizes promoter and enhancer elements for pluripotency genes including Oct4 to drive GFP [70] . It has also been found using vectors and transgenic mice that report on the activation of Wnt and Notch signaling, respectively, that both pathways are at their most active in HSCs and downregulate as differentiation proceeds [71, 72] . Going forward, this novel approach applied to cancer may offer an alternative and potentially more universal means to separate CSCs. Though few attempts have been made along these lines thus far, recent work by Vermeulen and colleagues demonstrates how successful this approach can be. In this work, the authors utilized a LEF/TCF reporter of Wnt activity in a murine model of APC and K-RAS-induced colon cancer. Despite observing a gradient of Wnt activation across all tumor cells, those cells having high Wnt activity were far more enriched for cells capable of cancer initiation when re-transplanted when compared to the intermediate or low Wnt signaling populations [73 • ]. In another example, MELK promoter GFP reporter mice have been exploited to show that in MMTV-Wnt1 induced breast tumors, the GFP ? populations are uniquely enriched for breast CSCs [74] . With the emergence of microRNAs as important regulators of stemness, there have also been efforts to use sensors of their presence as tools to enrich for stem cell populations. In particular, this method has been successfully utilized for the enrichment of human HSCs by detection of the elevated presence of mir-126 [75] and now awaits application to the CSC field. One can also envision the development of reagents that, along the lines of AL-DEFLUOR, rely on the detection of CSC-specific enzymes through assays that detect their modification of a known substrate.
Conclusion
In summary, as the search for CSC-targeted therapies continues to intensify, the ability to prospectively identify and isolate CSCs with high purity will be critical. As a mainstay methodology in this field, surface phenotyping is certainly not obsolete, but will likely benefit in the future from exploring candidate surface markers whose presence or absence is linked to the unique biological function of the CSC and/or in combining this approach with additional reporters of CSC functionality. 
